<DOC>
	<DOCNO>NCT02430974</DOCNO>
	<brief_summary>Epidermal growth factor receptor ( EGFR ) mutation occur 50 % Asian patient non-small cell lung cancer ( NSCLC ) . Treatment advance NSCLC patient EGFR-tyrosine kinase inhibitor ( EGFR-TKI ) confers significant survival benefit . This study assess efficacy safety chemotherapy without icotinib patient undergo resection stage IB IIIA EGFR-mutated NSCLC .</brief_summary>
	<brief_title>Chemotherapy NSCLC With Without Icotinib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Patients undergo completely resection EGRF mutationpositive NSCLC Staging ⅠB ( high risk factor ) ⅢA PS = 0 1 Adequate hematological , biochemical organ function Systemic anticancer therapy prior surgery , malignancy study , unstable illness , woman pregnant lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>